Aileron Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters11-15

* Aileron Therapeutics Inc reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -40 cents. The lone analyst forecast for the quarter was for a loss of 41 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Aileron Therapeutics Inc's reported EPS for the quarter was a loss of 27 cents​.

* The company reported a quarterly loss of $5.85 million.

* Aileron Therapeutics Inc shares had fallen by 6.5% this quarter and gained 8.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Aileron Therapeutics Inc is 13.00 This summary was machine generated from LSEG data November 15 at 02:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.41 -0.27 Beat

Jun. 30 2024 -0.42 -0.45 Missed

Mar. 31 2024 -0.14 -0.86 Missed

Dec. 31 2023 -0.16 -1.54 Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment